Wall Street Zen Upgrades Progyny (NASDAQ:PGNY) to Strong-Buy

Key Points

• Wall Street Zen upgraded Progyny from “buy” to “strong-buy.” Overall analyst sentiment is favorable: 11 analysts rate the stock Buy and four Hold, with a consensus price target of $34.92.
• Progyny reported quarterly EPS of $0.52, beating the $0.31 consensus estimate, and revenue of $341.25 million, up 8.9% year over year. The article also notes the company raised its full-year 2026 earnings guidance.
• Insiders sold 19,421 shares worth about $540,000 over the past quarter; institutional investors and hedge funds own approximately 94.93% of Progyny’s stock.

Progyny (NASDAQ:PGNY - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating in a report issued on Sunday, Wall Street Zen reports.

Several other equities research analysts have also commented on PGNY. Jefferies Financial Group set a $33.00 price target on shares of Progyny in a research note on Tuesday, September 8th. BTIG Research upped their price objective on shares of Progyny from $30.00 to $40.00 and gave the company a "buy" rating in a research note on Friday, July 24th. Canaccord Genuity Group set a $35.00 price objective on Progyny in a report on Friday, August 7th. Leerink Partners raised their price objective on Progyny from $37.00 to $38.00 and gave the stock an "outperform" rating in a report on Thursday. Finally, Wells Fargo & Company lifted their target price on Progyny from $37.00 to $38.00 and gave the stock an "overweight" rating in a research report on Thursday. Eleven research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, Progyny has an average rating of "Moderate Buy" and a consensus price target of $34.92.

Progyny Trading Up 1.4%

NASDAQ:PGNY opened at $34.84 on Friday. Progyny has a 12 month low of $16.10 and a 12 month high of $35.50. The stock has a 50 day moving average of $27.45 and a two-hundred day moving average of $24.59. The firm has a market cap of $2.67 billion, a P/E ratio of 31.96, a price-to-earnings-growth ratio of 2.40 and a beta of 0.97.

Progyny (NASDAQ:PGNY - Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The company reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.31 by $0.21. Progyny had a net margin of 6.80% and a return on equity of 19.82%. The business had revenue of $341.25 million during the quarter, compared to the consensus estimate of $340.76 million. During the same quarter in the previous year, the firm earned $0.15 EPS. The company's revenue was up 8.9% compared to the same quarter last year. On average, research analysts forecast that Progyny will post 1.25 earnings per share for the current year.

Insider Buying and Selling at Progyny

In related news, CFO Mark Livingston sold 2,139 shares of the company's stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $30.00, for a total value of $64,170.00. Following the completion of the sale, the chief financial officer owned 70,314 shares in the company, valued at $2,109,420. This represents a 2.95% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kevin Gordon sold 11,500 shares of the stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $27.94, for a total transaction of $321,310.00. Following the sale, the director owned 6,792 shares of the company's stock, valued at approximately $189,768.48. This represents a 62.87% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 19,421 shares of company stock valued at $539,960. Insiders own 9.90% of the company's stock.

Institutional Investors Weigh In On Progyny

Hedge funds have recently made changes to their positions in the business. Public Employees Retirement System of Ohio purchased a new position in shares of Progyny during the second quarter worth about $29,000. Nykredit A S purchased a new stake in Progyny during the 2nd quarter valued at approximately $38,000. IFP Advisors Inc raised its stake in Progyny by 376.0% during the 2nd quarter. IFP Advisors Inc now owns 1,961 shares of the company's stock valued at $57,000 after acquiring an additional 1,549 shares during the last quarter. Toth Financial Advisory Corp acquired a new stake in Progyny during the 2nd quarter worth approximately $65,000. Finally, Integrated Wealth Concepts LLC acquired a new stake in Progyny during the 2nd quarter worth approximately $74,000. Institutional investors and hedge funds own 94.93% of the company's stock.

Key Headlines Impacting Progyny

Here are the key news stories impacting Progyny this week:

• Positive Sentiment: Progyny reported third-quarter earnings of $0.52 per share and revenue of $341.25 million, slightly above the cited consensus revenue estimate. Revenue grew 8.9% year over year, while earnings increased from $0.15 per share a year earlier. Read More.
• Positive Sentiment: The company raised its full-year 2026 earnings guidance, a sign that management sees stronger earnings prospects. Read More.
• Positive Sentiment: Several analysts raised their price targets following the results: Citizens JMP and Leerink Partners moved to $38, while Cantor Fitzgerald raised its target to $35 and maintained an overweight rating. These revisions reinforce a favorable analyst view, although the targets imply varying degrees of potential upside. Read More.
• Neutral Sentiment: Coverage highlighted new client wins and margin expansion, but also noted a cautious market response. This suggests investors may be weighing growth and profitability improvements against expectations already reflected in the stock. Read More.

About Progyny

Progyny, Inc is a benefits-management company focused on fertility and family-building care. The company works with employers to provide comprehensive benefits that help members access fertility treatments and related services through a network of specialized providers.

Its offerings include coverage and support for services such as in vitro fertilization, fertility testing, egg and sperm freezing, donor services, gestational surrogacy, and adoption. Progyny also provides pharmacy benefits through Progyny Rx, as well as personalized guidance intended to help members navigate treatment options, providers, and the broader family-building process.

Progyny primarily serves self-insured employers and their employees in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.